UBS initiated coverage of Glaukos (GKOS) with a Buy rating and $182 price target While the shares trade at a high multiple versus peers, the premium is warranted by Glaukos’ “top-tier” growth profile, which has sales estimates tilted to the upside, the analyst tells investors in a research note. The firm says iDose is positioned to drive sales upside.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Tesla upgraded, Autodesk initiated: Wall Street’s top analyst calls
- Glaukos price target raised to $153 from $145 at Stifel
- Glaukos downgraded to Underweight from Equal Weight at Morgan Stanley
- Glaukos price target raised to $149 from $140 at BTIG
- Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval